Smith Kline Beckman Corporation v. Court of Appeals
REITERATIONFacts
The Antecedents: Smith Kline Beckman Corporation (petitioner), a U.S. corporation licensed to do business in the Philippines, filed an application for a patent for an invention entitled "Methods and Compositions for Producing Biphasic Parasiticide Activity Using Methyl 5 Propylthio-2-Benzimidazole Carbamate," which was granted as Letters Patent No. 14561. Tryco Pharma Corporation (private respondent) manufactures and sells a veterinary drug called Impregon, with Albendazole as its active ingredient. Procedural History: Petitioner sued private respondent for patent infringement and unfair competition, alleging that Impregon infringed Claims 2, 3, 4, 7, 8, and 9 of Letters Patent No. 14561 and constituted unfair competition. The Regional Trial Court (RTC) dismissed petitioner's complaint, declared Letters Patent No. 14561 null and void, ordered its cancellation, and awarded actual damages and attorney's fees to private respondent. The Court of Appeals (CA) affirmed the dismissal of the infringement and unfair competition claims but modified the RTC ruling by deleting the declaration of nullity and cancellation of the patent, and also deleted the award of actual damages and attorney's fees. The Petition: Petitioner filed a petition for review on certiorari, arguing that the CA erred in not finding that Albendazole is included in its Letters Patent No. 14561, thus constituting patent infringement, and in awarding damages and attorney's fees to private respondent.
Issue(s)
Whether private respondent committed patent infringement by manufacturing and selling Impregon with Albendazole as its active ingredient. Whether Letters Patent No. 14561 is void for violating patent law provisions. Whether private respondent is liable for unfair competition. Whether private respondent is entitled to actual damages and attorney's fees.
Ruling
The Supreme Court affirmed the Court of Appeals' decision with modification. It ruled that private respondent did not commit patent infringement. The Court deleted the award of actual damages and attorney's fees to private respondent but awarded temperate damages in the amount of P20,000.00.
Ratio Decidendi
On the issue of patent infringement: The Court held that petitioner failed to discharge the burden of proof to substantiate its claim of patent infringement. The claims of Letters Patent No. 14561 did not explicitly mention Albendazole, and no extrinsic evidence was adduced to prove that Albendazole inheres in the patent or that the patent's claims embrace it. While petitioner invoked the doctrine of equivalents, the Court found that petitioner's evidence failed to establish the substantial sameness of its patented compound and Albendazole. The Court emphasized that the doctrine of equivalents requires satisfaction of the function-means-and-result test, and petitioner did not prove that Albendazole operates in substantially the same way or by substantially the same means as the patented compound. The testimony of Dr. Orinion was deemed insufficient as he was not qualified as an expert witness on chemical compounds. Furthermore, the Court clarified that a divisional application signifies distinct inventions, meaning methyl 5 propylthio-2-benzimidazole carbamate is distinct from other inventions claimed in the original application, such as Albendazole. On the issue of the validity of Letters Patent No. 14561: The Court of Appeals correctly ruled that Letters Patent No. 14561 was not void, finding that the application was filed within the one-year period from the foreign application, complying with Section 15 of the Patent Law. The CA also sustained the presumption of correctness of the Patent Office's determination of patentability and that petitioner was the same assignee despite corporate name changes. On the issue of unfair competition: The Court of Appeals found that private respondent was not guilty of deceiving the public by misrepresenting that Impregon was its product, a finding affirmed by the Supreme Court. On the award of actual damages and attorney's fees: The Court disallowed the award of actual damages, stating that claims for lost profits must be supported by competent proof and the best evidence obtainable, such as documentary evidence, and not solely by the testimonies of corporate officers. The Court also disallowed attorney's fees, finding no sufficient showing of bad faith on the part of petitioner in filing the suit. However, the Court awarded temperate damages of P20,000.00 to private respondent, recognizing that it suffered some pecuniary loss the amount of which could not be established with certainty.
Main Doctrine
The doctrine of equivalents requires satisfaction of the function-means-and-result test, and the patentee bears the burden of proving that all three components of this test are met. Mere identity of result does not amount to infringement unless the infringing product operates in substantially the same way or by substantially the same means as the patented compound. Furthermore, claims of actual damages must be substantiated by competent proof and the best evidence obtainable, typically documentary evidence, and not solely by the testimonies of corporate officers.